Ovarian Hyperstimulation Syndrome (OHSS) is a potentially serious complication of assisted reproductive technology (ART). It is caused by an exaggerated response to the hormones used to stimulate ovulation during fertility treatments. OHSS can cause a wide range of symptoms, including abdominal pain, nausea, vomiting, and rapid weight gain. In severe cases, OHSS can lead to serious complications, including dehydration, thromboembolism, and even death. As such, it is important for doctors to be aware of the risk factors for OHSS, as well as strategies for prevention and management. This article provides an overview of OHSS, including risk factors, prevention strategies, and management options.
OHSS is a condition that occurs when the ovaries become overly stimulated in response to fertility medications. The ovaries become enlarged and produce an excessive amount of fluid, which can cause abdominal pain and distention. In some cases, the fluid can accumulate in the chest or abdomen, leading to further symptoms such as shortness of breath, nausea, and vomiting. OHSS can range from mild to severe, with the most severe cases requiring hospitalization.
There are several risk factors for OHSS. The most important factor is the type of fertility medication used. Medications that contain human chorionic gonadotropin (hCG) are more likely to cause OHSS than other types of fertility medications. Additionally, certain patient characteristics can increase the risk of OHSS, including age, body mass index (BMI), and ovarian reserve. Women with a higher BMI or lower ovarian reserve are more likely to experience OHSS.
There are several strategies that doctors can use to reduce the risk of OHSS. First, it is important to identify patients at high risk of OHSS before treatment begins. This can be done by assessing patient characteristics such as age, BMI, and ovarian reserve. Second, lower doses of hCG can be used for patients at high risk of OHSS. Third, doctors can use other fertility medications, such as clomiphene citrate, instead of hCG. Finally, doctors can use monitoring techniques such as ultrasound and blood tests to monitor the response to fertility medications and adjust the dose accordingly.
If OHSS does occur, it is important to take measures to manage the condition. Mild cases of OHSS can usually be managed at home with bed rest, fluids, and pain medication. In more severe cases, hospitalization may be necessary. In the hospital, patients may receive intravenous (IV) fluids, diuretics, and blood transfusions. In addition, doctors may recommend canceling the cycle of fertility treatment or freezing any embryos for transfer at a later date.
OHSS is a potentially serious complication of fertility treatments. as well as strategies for prevention and management. By taking steps to identify patients at high risk of OHSS and using appropriate monitoring techniques, doctors can reduce the risk of OHSS and ensure that appropriate management strategies are in place if the condition does occur.
1.
The use of biomarkers in the treatment of breast lumps is at a crossroads.
2.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
3.
How Do Younger People Fare With Stool Tests for CRC Screening?
4.
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
5.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
1.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
2.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
3.
Introduction to Immune Thrombocytopenic Purpura
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation